The global Erectile Dysfunction Drugs Market size is expected to reach USD 4.90 billion by 2030, expanding at a CAGR of 9.0% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of erectile dysfunction is expected to contribute to market growth. According to the European Association of Urology, the overall prevalence of ED was found to be around 52% in the European male population aged 40-70 years in 2020. In addition, according to the Boston University School of Medicine, approximately 22.0% of 40 years aged male population and 49.0% by age of 70 years are affected by erectile dysfunction. Thus, the increasing geriatric population is anticipated to increase the prevalence of ED over the forecast period and is expected to create lucrative growth opportunities in the market.
Eli Lilly and
Company is supporting ED patients by offering medicine at low cost through
Lilly Patient Support Program (LPSP). This program provides financial
assistance to eligible ED uninsured patients in Canada who may require
registration for this program. Thus, the presence of such supportive programs
for a branded version of Cialis may increase the affordability of the lower-income
patient population and also aid in generating increased revenue. Moreover,
companies have undertaken initiatives such as collaboration and partnership for
the manufacturing and commercialization of products in the overseas market. For
instance, in January 2022, Petros Pharmaceuticals Inc. partnered with a global
Contract Manufacturing Organization (CDMO) for the commercial production of
Avanafil tablets. This partnership was formed with an aim to replace the
existing agreement with Vivus Inc. and continue product supply.
Furthermore,
according to the National Library of Medicine (2021), a phase 3 clinical trial
was conducted by Sichuan Haisco Pharmaceutical Co., Ltd. to evaluate the safety
and efficacy of Stendra in patients with ED in mainland China. The results of
the clinical trial showed improvement in Chinese ED patients after
administration of two doses of Stendra 100 mg & 200 mg. Such proven
clinical effectiveness may strengthen Strenda’s (Avanafil) position in the
market. However, lack of awareness about erectile dysfunction, shame about
treatment, false-positive beliefs, social stigma pertaining to the disease, and
lack of discretion may restrain the market growth. As per the survey conducted
by the European Association of Urology (EAU), only 18% of the Spanish
population heard about ED treatment, whereas 68.0% of the population believes
the treatment benefits.
List of Key
Players in Erectile Dysfunction Drugs Market
- Bayer AG
- Lilly
- GSK plc.
- Petros Pharmaceuticals, Inc.
- Pfizer Inc.
- Teva Pharmaceutical
- Industries Ltd
- Lupin Limited
- Futura Medical
- Cure Pharmaceutical
- 23andMe (Lemonaid Health)
- Hims & Hers Health, Inc.
- Ro
- BlueChew
- GoodRx, Inc.
Related Press Release@ Erectile Dysfunction Drugs Market Report
Erectile
Dysfunction Drugs Market Report Highlights
- By product, the viagra segment held the largest
market share in 2023 due to the worldwide availability of Viagra and
increased awareness about the product among ED patients
- North America dominated the erectile dysfunction
drugs market and accounted for a revenue share of 51.3% in 2022, due to
the high burden of disease, strong healthcare infrastructure, and rapid
approval of new products for treatment in the region.
- Asia Pacific is expected to advance at the fastest
CAGR of 10.3% during the forecast period. The growth of the region is
attributable to the entry of new products into the region.
Erectile Dysfunction Drugs Market
Report Scope
|
Report Attribute |
Details |
|
Market
size value in 2024 |
USD 2.92
billion |
|
Revenue
forecast in 2030 |
USD 4.90
billion |
|
Growth
rate |
CAGR of
9.0% from 2024 to 2030 |
|
Actual
data |
2018 -
2023 |
|
Forecast period |
2024 - 2030 |
Inquire@ https://www.grandviewresearch.com/inquiry/2643/ibb
Erectile
Dysfunction Drugs Market Segmentation
Grand View
Research has segmented the global erectile dysfunction drugs market based on
product, route of administration, and region:
Erectile
Dysfunction Drugs Product Outlook (Revenue, USD Million, 2018 - 2030)
- Viagra (sildenafil citrate)
- Cialis (Tadalafil)
- Levitra/Staxyn (vardenafil)
- Stendra/Spedra (avanafil)
- Zydena (udenafil)
- Other Drugs
Erectile
Dysfunction Drugs Route of Administration Outlook (Revenue, USD Million,
2018 - 2030)
- Oral Mode of Administration
- Injectable Mode of Administration
- Other Modes of Administration
Erectile
Dysfunction Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Explore Horizon, the world's most expansive market
research database
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment